Volume | 251,680 |
|
|||||
News | (1) | ||||||
Day High | 39.42 | Low High |
|||||
Day Low | 38.70 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
38.75 | 38.70 | 39.42 | 38.71 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
8,200 | 251,680 | US$ 39.14 | US$ 9,849,558 | - | 29.85 - 45.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:33:07 | 1 | US$ 39.0932 | USD |
Halozyme Therapeutics Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.98B | 126.82M | - | 829.25M | 281.59M | 2.22 | 17.68 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Halozyme Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.35 | 39.42 | 37.73 | 38.33 | 790,550 | 0.74 | 1.93% |
1 Month | 40.57 | 41.60 | 37.73 | 39.59 | 885,391 | -1.48 | -3.65% |
3 Months | 34.26 | 42.64 | 33.15 | 38.74 | 1,047,257 | 4.83 | 14.10% |
6 Months | 35.00 | 42.82 | 32.83 | 37.58 | 1,170,636 | 4.09 | 11.69% |
1 Year | 34.27 | 45.00 | 29.85 | 37.45 | 1,096,459 | 4.82 | 14.06% |
3 Years | 49.67 | 59.46 | 29.85 | 41.15 | 1,101,114 | -10.58 | -21.30% |
5 Years | 16.09 | 59.46 | 12.71 | 34.75 | 1,197,794 | 23.00 | 142.95% |
Halozyme Therapeutics Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |